Ocugenix
Pittsburgh, US · Founded 2015 · Delaware corporation
Find your way into Ocugenix
Each arrow is one introduction. Sign up to fill in the first one.
Ask Robert Reilly to introduce you to Sean McDonald
You →Robert · together at Aethon →Sean
Sign up to find every way you can get introduced to Ocugenix
- Your email: who you already know at Ocugenix, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ocugenix team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.
Founders & leadership
Ocugenix was founded in 2015 by Sean McDonald.


Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 2 rounds · 2019–2021
▶$1.3MraisedSep 2021 · 8 investors · Other Health CareRule 506(b)
- Richard S. KollenderDirector
- Sean McDonaldExecutive Officer, Director
- Paul USA ChaneyDirector
- Thomas C. HohmanDirector
- Offering amount
- $4M
- Amount sold
- $1.3M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$350KraisedOct 2019 · 6 investors · Other Health CareRule 506(b)
- Sean McDonaldExecutive Officer, Director
- Richard S. KollenderDirector
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Ocugenix.
Frequently asked questions
- What does Ocugenix do?
- Ocugenix is a biotechnology company developing ophthalmology therapeutics based on NIH-funded research into the molecular mechanisms of wound healing and cellular response, originating from a research team at the University of Pittsburgh Medical Center. Its focus areas include eye diseases such as glaucoma and retinal conditions.
- Who founded Ocugenix?
- Ocugenix was founded by Sean McDonald in 2015.
- How much funding has Ocugenix raised?
- Ocugenix has disclosed $1.6M raised across 2 rounds.
- Where is Ocugenix headquartered?
- Ocugenix is headquartered in Pittsburgh, US.


